Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | KDM1A | O60341 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585964 | 1.00 | TRPV1 (0.68) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL15358922 | 0.91 | TRPV1 (0.58) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL14329163 | 0.87 | TRPV1 (0.53) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL5923227 | 0.86 | TRPV1 (0.73) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL20036237 | 0.86 | TRPV1 (0.62) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL5923219 | 0.86 | TRPV1 (0.73) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL2210228 | 0.86 | LTA4H (0.53) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL14092947 | 0.86 | ALDH1A1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL6002616 | 0.86 | ALDH1A1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL16407907 | 0.85 | TRPV1 (0.54) | TRPV1CYP1A2CYP3A4CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4210687-B1 | TRPV1 AGONISTS IN THE PREVENTION OF DIABETIC ULCERS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2026-05-27 | — | — | EP | claimed |
| EP-4739298-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| US-20260047592-A1 | NUTRITIONAL SUPPLEMENT COMPOSITION AND RELATED MANUFACTURING PROCESS | CHEN YUHUA (US) | 2026-02-19 | — | — | US | claimed |
| EP-4680210-A1 | MEDICAL PATCH COMPRISING SKIN IRRITATING ACTIVE AGENT | LTS Lohmann Therapie-Systeme AG (DE) | 2026-01-21 | — | — | EP | claimed |
| US-12274680-B2 | Treatment of benign prostatic hypertrophy with capsinoids | CREASY II GEORGE WILLIAM (US) | 2025-04-15 | — | — | US | claimed |
| WO-2025012137-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012667-A1 | ACTIVATORS OF THE XC-SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION. | SORBONNE UNIVERSITE (FR) | 2025-01-16 | — | — | WO | claimed |
| US-20250017251-A1 | DIETARY SUPPLEMENT CONTAINING CAYENNE PEPPER POWDER | PERFECT SPORTS INC (CA) | 2025-01-16 | — | — | US | claimed |
| US-12109268-B2 | Nanoparticle delivery system for targeted anti-obesity treatment | UNIVERSITY OF WYOMING (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024189213-A1 | MEDICAL PATCH COMPRISING SKIN IRRITATING ACTIVE AGENT | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-09-19 | — | — | WO | claimed |
| US-20230012268-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2023-01-12 | — | — | US | claimed |
| EP-4114372-A1 | USE OF QX314 TO PREVENT SYMPATHOEXCITATION ASSOCIATED WITH ADMINISTRATION OF TRPV1 MODULATORS | Neucures, Inc. (US) | 2023-01-11 | — | — | EP | claimed |
| EP-4072558-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR | Buzzelet Development And Technologies Ltd (IL) | 2022-10-19 | — | — | EP | claimed |
| WO-2022182940-A1 | NEURAL CONTROL OF ADAPTIVE IMMUNITY | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2022-09-01 | — | — | WO | claimed |
| US-20220233463-A1 | LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2022-07-28 | — | — | US | claimed |
| EP-4017486-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | Buzzelet Development And Technologies Ltd (IL) | 2022-06-29 | — | — | EP | claimed |
| US-20220168246-A1 | COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) | 2022-06-02 | — | — | US | claimed |
| WO-2022079574-A1 | COMPOSITIONS FOR REDUCING INFLAMMATION TO IMPROVE OR MAINTAIN MENTAL OR PHYSICAL HEALTH | GOODCAP PHARMACEUTICALS LTD. (CA) | 2022-04-21 | — | — | WO | claimed |
| WO-2022063372-A1 | ORAL ANTAGONIST COMPOSITIONS FOR NICOTINE BURNING RELIEF | FERTIN PHARMA A/S (DK) | 2022-03-31 | — | — | WO | claimed |
| EP-3968970-A1 | LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR | Buzzelet Development And Technologies Ltd (IL) | 2022-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260047592-A1 | NUTRITIONAL SUPPLEMENT COMPOSITION AND RELATED MANUFACTURING PROCESS | CHIA, COL2A1, COL1A1 | TRPV1 502/4885CYP1A2 2390/4885CYP3A4 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.